Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Pazopanib Hydrochloride
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Auro Pharma Arm Gets USFDA Nod for Pazopanib Tablet
Details :
Product Name : Vorient-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 05, 2024
Lead Product(s) : Pazopanib Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pazopanib Hydrochloride
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Eugia Pharma Receives USFDA Approval for Pazopanib Tablets, 200 mg
Details : Votrient-Generic (pazopanib HCl) is a multi-kinase inhibitor, which is indicated for the treatment of adults with advanced renal cell carcinoma & advanced soft tissue sarcoma.
Product Name : Votrient-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 05, 2024
Lead Product(s) : Pazopanib Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pazopanib Hydrochloride
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Midas Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Vorient-Generic (pazopanib) is a kinase inhibitor indicated for the treatment of patients with advanced renal cell carcinoma & advanced soft tissue sarcoma who have received prior chemotherapy.
Product Name : Vorient-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 26, 2021
Lead Product(s) : Pazopanib Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Midas Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable